
Product Data Sheet

Product Name: Olprinone

Cat. No.: GC36803

Chemical Properties

Cas. No. 106730-54-5

SMILES CC(N1)=C(C=C(C#N)C1=O)C2=CN3C(C=C2)=NC=C3Formula $C_{14}H_{10}N_4O$ M.Wt 250.26

Solubility DMSO : 50mg/mL Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure **Background**

Olprinone is an inhibitor of phosphodiesterase 3 (PDE3; $IC_{50} = 0.35 \mu M$ for human cardiac enzyme).¹ It is selective for PDE3 over PDE1 and PDE2 (IC_{50} s = 150 and 100 μM , respectively). Olprinone induces relaxation of precontracted isolated rabbit renal and carotid arterial rings (IC_{50} s = 40 and 103 nM, respectively).² It reduces infarct size and improves cardiac function in a rat model of myocardial ischemia-reperfusion injury when administered at a dose of 0.6 mg/kg twice per day.³ Olprinone (0.2 mg/kg) reduces cortical and striatal damage, as well as reduces injured cerebral tissue nitrotyrosine formation, apoptosis, and levels of inducible nitric oxide synthase (iNOS), IL-1 β , and intercellular adhesion molecule 1 (ICAM-1) in a rat model of cerebral ischemia-reperfusion injury.⁴ It inhibits neutrophil infiltration into the lungs and inhibits increases in serum levels of TNF- α and IL-6 in a rat model of LPS-induced lung inflammation when administered at a dose of 0.2 mg/kg.⁵

1. Sugioka, M., Masuoka, H., Ichikawa, K., et al. Identification and characterization of isoenzymes of cyclic nucleotide phosphodiesterase in human kidney and heart, and the

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

effects of new cardiotoxic agents on these isoenzymes Naunyn. Schmiedeberg's Arch. Pharmacol. 350(3)284-293(1994) 2. Minonishi, T., Ogawa, K., Tokinaga, Y., et al. Differential vasodilation response to olprinone in rabbit renal and common carotid arteries. J. Anesth. 24(1)61-66(2010) 3. Han, M.-X., Xu, X.-W., Lu, S.-Q., et al. Effect of olprinone on ischemia-reperfusion induced myocardial injury in rats. Biomed. Pharmacother. 111:1005-1012(2019) 4. Genovese, T., Mazzon, E., Paterniti, I., et al. Neuroprotective effects of olprinone after cerebral ischemia/reperfusion injury in rats. Neurosci. Lett. 503(2)93-99(2011) 5. Koike, T., Nadeen Qutab, M., Tsuchida, M., et al. Pretreatment with olprinone hydrochloride, a phosphodiesterase III inhibitor, attenuates lipopolysaccharide-induced lung injury via an anti-inflammatory effect. Pulm. Pharmacol. 21(1)166-171(2008)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA